ClinicalTrials.gg
CompletedNCT01476345Updated Oct 7, 2014Results posted

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

A Phase 1 interventional study of LY2963016 and Lantus in Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 1 site in South Africa. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.

Enrollment
41st of 81
80 · median 80
Started
2011
with 10 others
Phase 1
13 of 81
none open now
Registered
58th of 81
by date
Lead sponsor
7 of 81
Eli Lilly and Company

Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 41st largest by enrollment, is one of 11 that started in 2011, is one of 13 in phase 1, and was the 58th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing Insulin Glargine in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy participants.

Each study period will be approximately 8.5 days (1.5 days for treatment and 7 day washout period). There are 4 study periods.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are overtly healthy males or females, as determined by medical history and physical examination

    • male participants: agree to use a reliable method of during the study.
    • female participants of must test negative for pregnancy at the time of enrollment and agree to either abstain from sexual activity or to use a medically accepted means of contraception when engaging in sexual intercourse throughout the study, or female participants not of child-bearing potential due to surgical sterilization or menopause
  • have a body weight of at least 55 kilograms (kg), and (BMI) of 18.5 to 32.0 kilograms/square meter (kg/m²)
  • have clinical laboratory test results within normal reference range for the population
  • have venous access sufficient to allow for blood sampling
  • are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • have given written
  • participants should have a normal oral glucose tolerance test

Exclusion criteria

Exclusion Criteria:

  • are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an product other than the investigational product used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • have known allergies to heparin, insulin glargine, related compounds or any components of the formulation
  • are persons who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY2963016
  • have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • have an abnormal blood pressure as determined by the investigator
  • have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication
  • show evidence of significant active neuropsychiatric disease
  • regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • show evidence of (HIV) infection and/or positive human HIV antibodies
  • show evidence of and/or positive hepatitis C antibody
  • show evidence of and/or positive hepatitis B surface antigen
  • are women with a positive pregnancy test or women who are lactating
  • intend to use over-the-counter or prescription medication
  • have donated blood of more than 500 milliliters (mL) within the last 56 days before dosing of Period 1
  • have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption for 24 hours before dosing and throughout the duration of each study period
  • smoke more than 10 cigarettes (or equivalent other tobacco products) per day
  • have a fasting blood glucose > 5.5 millimoles/Liter (mmol/L) [>99 milligrams/deciliter (mg/dL)]at screening
  • have a positive test for anti-LY2963016 or anti-glargine antibodies
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    LY2963016

    A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.

    Drug: LY2963016

  • Experimental
    Lantus

    A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.

    Drug: Lantus

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus

    Time frame: 1 hour predose up to 24 hours postdose in all treatment periods

  2. Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus

    Time frame: 1 hour predose up to 24 hours postdose in all treatment periods

Secondary outcomes

  1. Maximum Glucose Infusion Rate (Rmax)

    Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 1 hour predose up to 24 hours postdose in all treatment periods

  2. Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure

    Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 1 hour predose up to 24 hours postdose in all treatment periods

07

Results

Posted Oct 7, 2014

Participant flow

Period 1
Participant flow — Period 1
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4040
Received at least 1 dose of study drug4040
Completed4040
Not completed00
Period 2
Participant flow — Period 2
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4040
Completed4040
Not completed00
Period 3
Participant flow — Period 3
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started3939
Completed3939
Not completed00
Period 4
Participant flow — Period 4
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started3939
Completed3939
Not completed00

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus
Time frame:
1 hour predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · picomoles*hour/Liter (pmol*h/L)
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus
picomoles*hour/Liter (pmol*h/L)LY2963016Lantus
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus1810 ± 401980 ± 36
PrimaryPharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus
Time frame:
1 hour predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · picomoles/Liter (pmol/L)
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus
picomoles/Liter (pmol/L)LY2963016Lantus
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus112 ± 39119 ± 34
SecondaryMaximum Glucose Infusion Rate (Rmax)

Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
1 hour predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · milligrams/kilogram/minute (mg/kg/min)
Maximum Glucose Infusion Rate (Rmax)
milligrams/kilogram/minute (mg/kg/min)LY2963016Lantus
Maximum Glucose Infusion Rate (Rmax)2.85 ± 462.88 ± 41
SecondaryTotal Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure

Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
1 hour predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · milligrams/kilogram (mg/kg)
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
milligrams/kilogram (mg/kg)LY2963016Lantus
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure2580 ± 452710 ± 40

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016—0/80 (0%)50/80 (62.5%)
Lantus—0/80 (0%)54/80 (67.5%)
Most frequent other events
Most frequent other events
EventLY2963016Lantus
HeadacheNervous system disorders15/8025/80
Procedural site reactionInjury, poisoning and procedural complications17/8017/80
Injection site painGeneral disorders5/806/80
NauseaGastrointestinal disorders4/805/80
DiarrhoeaGastrointestinal disorders4/801/80
Injection site erythemaGeneral disorders4/802/80
DysmenorrhoeaReproductive system and breast disorders1/240/24

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean32.0 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female24
Male56
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American10
White64
More than one race6
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)All Participants
South Africa80
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloemfontein, 9301, South Africa
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2011
First posted
Nov 22, 2011
Start
Nov 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01476345
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Nov 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion